A randomized clinical trial in adults and newborns in South Africa to compare the safety and immunogenicity of bacille Calmette-Guérin (BCG) vaccine administration via a disposable-syringe jet injector to conventional technique with needle and syringe  by Geldenhuys, Hennie D. et al.
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Introduction:  Intradermal  bacille  Calmette-Guérin  (BCG)  vaccination  by needle-free,  disposable-syringe
jet  injectors  (DSJI)  is  an  alternative  to  the  Mantoux  method  using  needle  and  syringe  (NS).  We  compared
the  safety  and  immunogenicity  of  BCG  administration  via the  DSJI  and  NS  techniques  in adults  and
newborn  infants  at the  South  African  Tuberculosis  Vaccine  Initiative  (SATVI)  research  site  in  South  Africa.
Method:  Thirty  adults  and 66 newborn  infants  were  randomized  1:1 to  receive  intradermal  BCG  vaccine
(0.1  mL  in  adults;  0.05  mL  in infants)  via  DSJI  or NS.  Wheal  diameter  (mm)  and  skin  ﬂuid  deposition  at  the
site  of  injection  (SOI)  were  measured  immediately  post-vaccination.  Adverse  events  and  SOI  reactogen-
icity  data  were  collected  30 min  and  1, 2, 4, and 12  weeks  after vaccination  for adults  and  at  30 min  and
4,  10, and  14 weeks  for infants.  Blood  was  collected  in  infants  at 10 and  14  weeks  to  assess  BCG-speciﬁc
T-cell  immune  responses.
Results:  More  infant  BCG  vaccinations  by  DSJI  deposited  >5 L ﬂuid  on the  skin surface,  compared  to
NS  (49%  versus  9%,  p =  0.001).  However,  all 12 infant  vaccinations  that did not  produce  any  SOI  wheal
occurred  in  the  NS group  (36%,  p  < 0.001).  Median  wheal  diameter,  in  participants  for  which  an  SOI wheal
formed,  did  not  differ  signiﬁcantly  between  groups  in infants  (combined  3.0  mm  IQR 2.0  to  4.0,  p =  0.59)
or  in  adults  (combined  9.0  mm  IQR 7.0  to 10.0, p  = 0.13).  Adverse  events  were  similar  between  study
arms.  Proportion  of  participants  with  BCG  scars  after  three  months  did not differ  in  adults  (combined
97%,  p = 0.67)  or infants  (combined  62%,  p = 0.13).  Frequencies  of  BCG-speciﬁc  clusters  of  differentiation  4
(CD4) and  clusters  of  differentiation  8 (CD8)  T-cells  co-expressing  IFN-,  TNF-,  IL-2, and/or  IL-17  were
not  different  in the DSJI and  NS  groups.
Conclusion:  BCG  vaccination  of  newborn  infants  via  DSJI was  more  likely  to  deliver  an  appropriate  intra-
dermal  wheal  at the  SOI as c
Safety,  reactogenicity,  and an
NS  techniques.
© 2015  The  Authors.  Publis
Abbreviations: AE, adverse event; BCG, bacille Calmette-Guérin; CD4/CD8, cluster of d
CS,  intracellular cytokine staining; IQR, interquartile range; NS, needle and syringe; SATVI,
h1,  T helper type 1 cells.
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. Introduction
Disposable-syringe jet injectors (DSJI) are needle-free admin-
stration devices for parenteral vaccines. DSJIs are designed to be
ugged and easy for health care workers to learn to use; they may
ontribute to more consistent vaccine administration in the ﬁeld
s compared to conventional administration by needle and syringe
NS) [1,2]. These factors may  be particularly useful for intrader-
al  vaccines, such as bacille Calmette-Guérin (BCG), for which the
ntradermal administration by the Mantoux delivery method with
S (termed Mantoux) is technically challenging to successfully per-
orm [3].
BCG, the only licensed vaccine against tuberculosis (TB), is the
ost widely administered intradermal vaccine in the world. It is
iven shortly after birth in many TB-endemic countries. Global BCG
overage is high (80% to 90%) and is part of the routine immuniza-
ion program in more than 169 countries [4,5]. BCG is known to
nduce a robust T helper type 1 (Th1) immune response against a
umber of TB antigens present in Mycobacterium tuberculosis [6].
B remains a huge global health problem. In 2012, more than 8.6
illion people developed the disease and 1.3 million died of it [7].
CG and future novel TB vaccines represent an important strategy
n combating this major disease [8].
BCG vaccine administration must be optimal to achieve
aximum effectiveness. The conventional technique for BCG
dministration is intradermal vaccination with NS by the Mantoux
echnique. This technique requires exact placement and the cor-
ect angle of insertion and orientation of the needle point into the
ntradermal layer of the skin; otherwise, the deposition of vaccine
uid is either too deep (subcutaneous) or too superﬁcial (poten-
ially leaking ﬂuid on the skin surface). The Mantoux technique is
echnically complex and requires training, experience, and optimal
hysical conditions to perform correctly [3].
Intradermal vaccine administration via DSJI may  be simpler and
ore consistent than Mantoux NS techniques. DSJI devices employ
eedle-free technology to deliver injectable ﬂuid into the intrader-
al, subcutaneous, or intramuscular layers of tissue under high
ressure through a small nozzle. Although the DSJI hand piece is
esigned to be reusable and robust for use in the ﬁeld, the com-
onent that comes into contact with the patient (designated the
eedle-free syringe or cartridge) is single-use and disposable. The
dvantages of this technology include a simpliﬁed administration
echnique that may  be less dependent on user skill and requires
impler user training and experience. It eliminates the risk of nee-
le reuse or needlestick injuries and potentially offers a less variable
eposition of vaccine ﬂuid into the intended layer of skin [3]. Much
f the work with DSJIs has focused on the potential for dose-sparing
y intradermal administration of vaccines traditionally adminis-
ered intramuscularly, such as inﬂuenza and inactivated poliovirus
accines [9–11]. Although previous generations of multi-use noz-
le jet injectors were widely used for BCG administration, the new
eneration of improved DSJI devices has not yet been evaluated
or BCG vaccination [12]. Given the potential advantages of DSJI,
ur objective was to test whether BCG vaccination via DSJI was
afe and immunogenic when compared to BCG vaccination via the
onventional Mantoux NS method.
. Methods
.1. Study design and settingWe  employed a partially blinded, randomized clinical trial
esign to compare BCG vaccination via the experimental DSJI to
tandard-of-care NS. The trial was conducted in two  stages: an
dult stage, to exclude a major safety signal, before proceedinge 33 (2015) 4719–4726
to an infant stage, during which newborns were vaccinated. BCG
vaccination shortly after birth is routine in this TB-endemic study
population, which represents the target population for the inter-
vention. In both stages, a random 1:1 allocation was  performed
into standard-dose, intradermal BCG vaccination via DSJI or via NS.
The DSJI device used in this study was  the Bioject ID Pen (Bioject,
USA). The ID Pen is a small, compact spring-powered device that
uses an autodisable, single-use disposable syringe with a spacer
to limit ﬂuid deposition to the intradermal tissue. The BCG Danish
strain 1331 (Staten Serum Institut, Denmark) was  administered at a
standard dose of 0.1 mL  or 2–8 × 105 colony forming units (CFU) in
adults and 0.05 mL  or 1–4 × 105 CFU in infants. The trial was  con-
ducted in the Worcester region of the Western Cape Province in
South Africa, at the research site of the South African Tuberculosis
Vaccine Initiative (SATVI) [13].
Approval was  obtained from the Human Research Ethics Com-
mittee of the University of Cape Town, the PATH Research Ethics
Committee, and the World Health Organization Ethics Review Com-
mittee. A local medical monitor and a data safety monitoring board
oversaw participant safety, which was  required per protocol to
approve progression from the adult stage to the infant stage and the
continuation of enrollment after the ﬁrst 20 vaccinated infants. The
trial was  registered on ClinicalTrials.gov (NCT01742364) and South
African National Clinical Trials Register (DOH-27-1112-4239)
[14].
2.2. Screening, randomization, and vaccination
For the adult stage, 30 healthy adults from 18 to 50 years of
age were enrolled after undergoing screening, which occurred after
signed informed consent. Participants were excluded if they had
major concomitant medical conditions; were HIV positive; or had
a household TB contact, a history of TB disease, a chest X-ray sug-
gestive of previous TB disease, or a positive test for TB infection
(Quantiferon TB-Gold test; Cellestis, Australia).
For the newborn vaccination stage, 66 infants were enrolled.
Informed consent was obtained from the mothers of potential
infant participants during the later stages of pregnancy. Study
inclusion required mothers to have a documented negative HIV
test and an uncomplicated pregnancy and delivery. Caesarian sec-
tions for maternal indications were allowed. Newborns needed to
have an Apgar score ≥7 at 5 min, birth weight ≥2500 g, estimated
gestation ≥38 weeks, and be in good general health to be eligible
for enrollment. Gestation age was determined using the best esti-
mate combination of last menstrual period, clinical assessment, and
pregnancy ultrasound where available.
The vaccinating nurse was unblinded, but did not take part in
follow-up assessments. The remainder of the study team remained
blinded to study group allocation until database lock. Parents
were not present during infant vaccination, and were therefore
blinded. However, adult participants could not be blinded. Vac-
cinations were performed by three research nurses who  received
hands-on training for the DSJI device and Mantoux NS technique,
including proﬁciency testing. Vaccination of adults occurred at
the clinical trial site. Vaccination of infants occurred at com-
munity birthing units within a maximum of 48 h after birth. In
the adults and infants, random study group allocation by partic-
ipant study number was pre-determined by a randomization list
prepared by the blinded data manager using a random number
generator. After enrollment and study number assignment, andsealed individual envelopes labeled with the participant number
and marked inside with the pre-assigned group allocation. The
envelopes were then immediately destroyed to prevent inadver-
tent unblinding.
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.3. Post-vaccination follow-up
Adults were seen 1, 2, 4, and 12 weeks after vaccination. Infants
ttended study visits 4, 10, and 14 weeks after vaccination, and
arents were contacted by telephone 1, 7, and 14 days after vacci-
ation. Phlebotomy for immunogenicity was performed at 10 and
4 weeks in infants only.
.4. Clinical endpoint data collection
Three groups of clinical data were collected: injection perfor-
ance data, including wheal diameter (measured in millimeters)
nd skin ﬂuid deposition at the site of injection (SOI) immediately
ost-vaccination; safety data (adverse events [AEs], including sys-
emic reactions); and speciﬁc characteristics of the BCG SOI lesion
ulcer and scar formation).
Wheal diameter was measured with a transparent ruler imme-
iately after vaccination. Skin ﬂuid deposition at the injection site
as estimated in adults using an observational scale immediately
fter vaccination (skin damp, ﬂow of ﬂuid on skin, ﬂuid spray in air,
uid runs out of injection site, “wet shot”). A vaccination was con-
idered a “wet shot” when all the administered ﬂuid was observed
o be located on the skin surface and not properly injected at the
esired intradermal depth. Skin ﬂuid deposition at the injection site
as measured in infants using an objective ﬁlter paper technique
PATH, unpublished data). The ﬁlter paper was applied to the skin
mmediately after vaccination. Fluid absorbed by the paper caused
 demarcated patch, the diameter of which was measured. Patch
iameters had been correlated pre-trial with standardized ﬂuid
olumes and reported in six categories (≤2.5 L, ≤5 L, ≤10 L,
20 L, ≤40 L, >40 L).
Adverse events were collected 30 min  following vaccination and
uring follow-up visits through history and examination and par-
icipant diaries. The AEs were graded for severity and causality by
n investigator. All AEs were recorded, including characteristic BCG
ite of injection reactions such as erythema, induration, ulcer, and
car formation. AEs were classiﬁed as “injection site reactions” if
hey occurred at the site of vaccine administration; all other AEs
ere classiﬁed as “systemic.”
.5. Immunogenicity endpoint data collection
BCG-speciﬁc immunogenicity was tested in infants only, since
hey are the target study population and BCG immunogenicity
n adults is known to be different from that in infants. Currently
here are no known immune-correlates of protection against TB;
herefore, utilizing a whole blood intracellular cytokine stain-
ng (ICS) assay, we analyzed cytokine co-expression patterns by
CG-speciﬁc CD4 and CD8 T-cells [15]. Brieﬂy, 0.5 mL  heparinized
hole blood was incubated for 12 h with BCG (1.2 × 106 CFU/mL,
tatens Serum Institut), no antigen or phytohemagglutinin (PHA)
10 g/mL, Sigma-Aldrich,  USA) in the presence of anti-CD28
nd anti-CD49d (0.5 g/mL each, BD Biosciences, USA), with the
ast 5 h including Brefeldin A (10 g/mL, Sigma-Aldrich)  prior
o treating with BD FACSTM Lysing Solution (BD Biosciences)
nd cryopreservation. Cells were batch-thawed, permeabilized
ith BD Perm/WashTM buffer (BD Biosciences) and stained with
uorescent antibodies as follows: CD3-BV421 (clone UCHT1),
D8-PerCPCy5.5 (SK1), CCR7-PE (150503), IFN--AlexaFluor700
B27), IL-17-AlexaFluor647 (SCPL1362), IL-2-FITC (5344.111, all
rom BD Biosciences), TNF--PECy7 (MAb11, eBiosciences, USA),
D45RA-BV570 (HI100, BioLegend,  USA), and CD4-QDot605 (S3.5,
ife Technologies, USA). At least 120,000 CD3+CD4+ T-cells were
cquired for the no-antigen and BCG samples on a BDTM LSR II ﬂow
ytometer (BD Biosciences).e 33 (2015) 4719–4726 4721
2.6. Sample size and analysis
The sample size of 30 for the adult group was selected as ade-
quate to demonstrate safety before progressing to infants, allowing
detection of severe AEs occurring in 6% of the study population,
bound on the upper 95% conﬁdence interval.
Calculation of sample size for the infant group was  based on the
primary immunogenicity endpoint. A sample size of 66 participants
(33 per study group) would allow demonstration of an effect size
of 33% for difference in frequency of CD4+ cytokine-producing cells
with a power of 80% and alpha 0.05 and attrition of 10%, based on
expected mean response and variation in previously published data
[16].
Site of injection reactogenicity and injection performance were
analyzed using Stata data analysis and statistical software (Stat-
aCorp, USA). Frequency of AEs and measurement of injection
performance and BCG lesion parameters were compared between
study groups using the Kruskal–Wallis test, Fisher’s exact test, and
the Chi-square test for trend. A p-value of ≤0.05 was  considered
statistically signiﬁcant.
Immunogenicity data analysis was performed with FlowJo
cytometry data analysis software version 9.0 (TreeStar, USA) with
Supplementary Fig. 1 illustrating hierarchical gating strategy. The
Boolean gate platform was used with individual cytokine gates
to create all possible response pattern combinations. The data
analysis programs PESTLE (version 1.7) and SPICE (Simpliﬁed Pre-
sentation of Incredibly Complex Evaluations, version 5.32) were
used to subtract background responses (unstimulated control)
from antigen-speciﬁc responses and to analyze ﬂow cytometry
data (both provided by Mario Roederer; Vaccine Research Center,
US National Institute of Allergies and Infectious Diseases, US National
Institutes of Health,  2013) [17]. Statistical analysis and graphs were
performed using Prism software version 6 (GraphPad,  USA). T-cell
responses between the DSJI and NS groups were compared using
Mann–Whitney U tests; a p-value of ≤0.05 was considered signiﬁ-
cant. To account for the multiple testing, the Bonferroni adjustment
was applied where applicable. Adjusted p-values considered to
be signiﬁcant when comparing multiple cell subsets and/or time
points are indicated in the ﬁgure legends.
3. Results
3.1. Participant allocation and baseline
At baseline, age and gender distributions were similar by study
arm allocation in adults, and gestation period, birth weight, and
gender distributions were similar by study arm allocation in infants
(Table 1). All infants were vaccinated within 24 h of birth. No par-
ticipants were lost to follow-up (Fig. 1).
3.2. Injection performance
Among adults, a site of injection (SOI) wheal formed in all vac-
cinations, and median wheal diameter did not differ between DSJI
and NS (p = 0.13). Among the 66 infants who were vaccinated, 12
(18.2%) had no visible wheal at the SOI. All 12 infants without a
visible wheal were in the NS group (Table 2, p = 0.001). In the 54
infants on whom an SOI wheal was observed (i.e., wheal diameter
>0 mm), the median wheal diameter did not differ between study
arms (p = 0.588) (Fig. 2B). In a sensitivity analysis, including those
infants without a visible wheal (i.e., wheal diameter = 0 mm)  in the
comparison, median wheal diameter was signiﬁcantly lower in the
NS group (2.0 mm;  IQR 0.0 to 3.0 in NS versus 3.0 mm;  IQR 2.0 to
3.0 in DSJI; p = 0.032).
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Table  1
Baseline characteristics of adult and infant participants. There were no differences between the study groups.
Combined Jet injector (DSJI) Needle and syringe (NS)
Adults n = 30 n = 15 n = 15
Median age in years (IQR) 34.5 (22.0–41.0) 29.0 (21.0–43.0) 35.0 (22.0–41.0)
Female gender, n (%) 23 (76.7%) 13 (86.7%) 10 (66.7%)
Vaccinator
Nurse 1 13 (43.3%)* 7 (53.8%) 6 (46.2%)
Nurse 2 12 (40.0%) 6 (50.0%) 6 (50.0%)
Nurse 3 5 (16.7%) 2 (40.0%) 3 (60.0%)
Infants n = 66 n = 33 n = 33
Female gender, n (%) 34 (51.5%) 18 (54.5%) 16 (48.5%)
Median birth weight in grams (IQR) 3140 (2940–3420) 3060 (2960–3510) 3155 (2940–3360)
Median gestation in weeks (IQR) 39 (38–40) 39 (38–40) 40 (38–40)
Type  of delivery, n (%)
Normal delivery 50 (75.8%) 28 (84.8%) 24 (72.7%)
Assisted 1 (1.5%) 0 (0.0%) 1 (3.0%)
Caesarean section 15 (22.7%) 5 (15.2%) 8 (24.2%)
Vaccinator
Nurse 1 31 (46.9%)* 14 (45.2%)* 17 (54.8%)*
Nurse 2 24 (36.4%) 14 (58.3%) 10 (41.7%)
Nurse 3 11 (16.7%) 5 (45.5%) 6 (54.5%)
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dQR: interquartile range.
* Proportions of vaccinations performed by each nurse are shown as percentages
In adults, all 15 (100%) DSJI injections resulted in dampness on
he skin, compared to 8 (53.3%) in the NS group. No “wet shots,”
unning or ﬂowing ﬂuid on the skin, or ﬂuid spray above the sur-
ace of the skin were observed in either group. Signiﬁcantly more
nfant vaccinations by DSJI resulted in skin ﬂuid deposition at the
ite of injection (p = 0.001 by Chi-square test for trend, Table 2).
ore infant DSJI vaccinations resulted in skin ﬂuid deposition
5 L, compared with NS (n = 16, 48.5% versus n = 3, 9.0%; p = 0.001;
able 2
njection performance parameters (wheal diameter and skin ﬂuid deposition immediatel
Combined Je
Adults n = 30 n
Wheal diameter (mm)
No wheal 0 0
Wheal > 0 mm,  n (%) 30 (100%) 1
Median (IQR) mm* 9.0 (7.0–10.0) 7
Skin  ﬂuid deposition category, n (%)
No wetness 7 (23.3%) 0
Damp  skin 23 (76.7%) 1
Flow  on skin 0 0
Spray in air 0 0
Fluid  runs out inj. site 0 0
Complete wet  shot 0 0
Infants n = 66 n
Wheal Diameter (mm)
No wheal 12 (18.2%) 0
Wheal > 0 mm,  n (%) 54 (81.8%) 3
Median (IQR) (mm)* 3.0 (2.0–4.0) 3
Skin  ﬂuid deposition category, n (%)
A:  ≤2.5 L 33 (50.0%) 5
B:  >2.5–≤5 L 14 (21.2%) 1
C:  >5–≤10 L 15 (22.7%) 1
D:  >10–≤20 L 4 (6.1%) 2
E:  >20–≤40 L 0 0
F:  >40 L 0 0
>5  L cumulative** (C + D + E + F combined) 19 (28.8%) 1
>10  L cumulative** (D + E + F combined) 4 (6.1%) 2
QR: Interquartile range. Wheal diameter (in mm)  was  measured by ruler. For adults, the
olume was  measured objectively and categorized by the ﬁlter paper technique. p-Value
iameters using Kruskal–Wallis test, and difference in proportions using Fisher’s exact te
* Includes only wheal sizes >0 mm in infants. All wheal sizes were >0 mm in adults.
** 5 L = 10% of injected volume of 0.05-ml infant dose. 10 L = 20% of injected volume. total number of vaccinations and administration method.
represented as proportions in Fig. 2A). However, the frequency of
skin ﬂuid deposition ≥10 L was  equal in the two  groups (n = 2
versus n = 2, 6.1%) (Table 2).
There was no association between wheal diameter and skin
ﬂuid deposition score (r = 0.1, p = 0.610), date of vaccination (r = 0.2,
p = 0.144), or vaccinating study team member (r = 0.3, p = 0.200). The
12 vaccinations in the NS group with a 0.0-mm wheal diameter
were not associated with a particular time period or vaccinator and
y post-vaccination) by study group.
t injector (DSJI) Needle and syringe (NS) p-Value
 = 15 n = 15
 0
5 (100%) 15 (100%)
.0 (5.0–10.0) 9.0 (8.0–10.0) p = 0.130
 7 (46.6%)
5 (100%) 8 (53.3%) p = 0.003
 0
 0
 0
 0
 = 33 n = 33
 12 (36.4%)
3 (100%) 21 (63.6%) p = 0.001
.0 (2.0–3.0) 3.0 (2.0–4.0) p = 0.588
 (15.2%) 28 (84.8%)
2 (36.3%) 2 (6.1%)
4 (42.4%) 1 (3.0%) p = 0.001
 (6.1%) 2 (6.1%)
 0
 0
6 (48.5%) 3 (9.1%) p = 0.001
 (6.1%) 2 (6.1%)
 skin ﬂuid deposition was estimated and categorized by the vaccinator; for infants,
s for ﬂuid deposition categories calculated using Chi-square test for trend, wheal
st.
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Screened for  eligibili ty 
 Adults (n=95) 
 Infants (n= 131 )  
Excluded (n =130)
 Not mee ting  inclusion  criteria 
    Adults (n =63)     
   Infants (n=50)  
 Refused to participate  
   Adults (n=2)    
Infants (n=0) 
 Eligible  but  enrollment t arget 
 reached prior to enrollment (n=15)   
Randomized  (n=96)  30  adults,  66 in fan ts    
DSJI:
Adul ts (n =15) 
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  Adults ( n=15) 
  Infants (n=33) 
Lost to follow-up  (n =0)    
Withdrew consent   
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tig. 1. Consort ﬂow diagram summarizing participant recruitment, allocation, and
etention.
id not result in more or fewer AEs or altered immunogenicity (data
ot shown).
.3. Adverse events and BCG lesions
No differences in frequencies of AEs between the DSJI and NS
tudy arms were observed in either infants or adults. The major-
ty of AEs were characteristic injection-site, BCG-associated lesions
hat did not differ in frequency between the study groups (Table 3).
t 12 and 14 weeks post-vaccination, 96.7% of adults, but only 62.1%
f infants, had developed a visible BCG scar at the site of injec-
ion. No difference was detected in proportion of scar formation by
ig. 2. Site of injection (SOI) skin ﬂuid deposition and wheal diameter (in millimeters)
nfants with measured SOI skin ﬂuid deposition scores that fall into the categories ≤2.5 
ases  of ﬂuid deposition in the 20–40 L or >40 L categories. (B) Wheals that were und
njector [DSJI]). Horizontal lines represent medians, boxes represent interquartile range 
est,  comparing the NS group versus the DSJI group.e 33 (2015) 4719–4726 4723
14 weeks between infants in the DSJI group (n = 24, 72.7%) and NS
group (n = 17, 51.5%) (p = 0.127).
3.4. Immunogenicity
Antigen-speciﬁc CD4 and CD8 T-cells expressing IFN-, TNF-
, IL-2, and/or IL-17 were measured by whole blood ICS assay
and multi-parameter ﬂow cytometry (Supplementary Fig. 1).
Both administration methods induced BCG-speciﬁc Th1 responses,
which were readily detectable in all infants 10 and 14 weeks after
vaccination (Fig. 3A). The most prominent CD4 cytokine-producing
subsets expressed IFN- alone, or co-expressed IFN-, TNF- and
IL-2 or IFN- and TNF- (bifunctional cells) (Fig. 3C and D). Fre-
quencies of these Th1 subsets were not different in the DSJI and
NS groups, either at 10 or at 14 weeks (Fig. 3A). IL-17-expressing
BCG-speciﬁc CD4 T-cells occurred at a very low frequency and were
mostly not detected in both groups (data not shown).
BCG-speciﬁc CD8 T-cells were largely restricted to producers of
IFN- alone at 10 and 14 weeks after vaccination (Fig. 3E and F). As
observed for CD4 T-cells, frequencies of cytokine-expressing BCG-
speciﬁc CD8 T-cells were not different in the DSJI and NS groups
(Fig. 3B). BCG-speciﬁc CD4 and CD8 T-cells expressing any or all
cytokines were also similar in the NS group, irrespective of wheal
presence or absence or stratiﬁcation by wetness of >5 L or <5 L
(Fig. 4A and B, data not shown). The pattern of CD4 cytokine-
producing subsets expressing IFN- alone, co-expressing IFN-,
TNF- and IL-2 or IFN-and TNF- (bifunctional cells) remained the
same irrespective of wheal formation or stratiﬁcation by wetness
of >5 L or <5 L (data not shown).
4. Discussion
In this partially blinded, randomized clinical trial, BCG vaccina-
tion of adults and infants, either by standard-of-care Mantoux NS
technique or DSJI, resulted in safety proﬁles and BCG-speciﬁc T-
cell immune responses that did not differ between administration
methods. No differences in injection performance were detected in
adults. In infants, we  observed an increased rate of small-volume
skin ﬂuid deposition by DSJI. A number of infant vaccinations with
NS did not form a wheal, whereas all DSJI vaccinations formed a
visible wheal. To our knowledge, these are the ﬁrst published dataeters and BCG immunogenicity.
All 12 of the BCG vaccinations that did not form a visible site of
injection wheal in infants were performed using NS (36%) whereas
 measured immediately post-vaccination of BCG in infants. (A) The proportion of
L, >2.5–5 L, >5–≤10 L, >10–≤20 L are represented in pie charts. There were no
etectable in infants are not included (zero mm:  12 needle and syringe [NS], 0 jet
(IQR), and whiskers the range. p-Values were calculated using the Kruskal–Wallis
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Fig. 3. Frequencies of CD45RAlow BCG-speciﬁc CD4 and CD8 T-cell responses measured by whole blood ICS in infants (n = 31 jet injector [DSJI], n = 30 needle and syringe [NS]).
The  hierarchical gating strategy is illustrated in Supplemental Fig. 1. Shown are frequencies of all cytokine-expressing (any cell expressing IFN-, TNF-, IL-2 and/or IL-17)
BCG-speciﬁc CD4 (A) and CD8 (B) T-cell responses at 10 or 14 weeks after vaccination. (C–F) Frequencies of BCG-speciﬁc CD4 (C and D) and CD8 (E and F) T-cells co-expressing
different combinations of IFN-, TNF-, and IL-2 measured 10 weeks (C and E) or 14 weeks (D and F) after BCG vaccination; IL-17-expressing cells were extremely low or not
detected. Horizontal lines represent medians, boxes represent interquartile range (IQR), and whiskers the range. Each individual vaccinee is represented by a dot. p-Values
were  calculated using the Mann–Whitney test, comparing the NS group versus the DSJI group per time point or per cytokine-expressing cell subset. In (C–F), following
Bonferroni adjustment a p-value of less than 0.007 was considered signiﬁcant.
Fig. 4. Frequencies of BCG-speciﬁc CD4 and CD8 T-cell responses measured by whole blood ICS in infants separated by the development of a wheal (n = 18) or no wheal
(n  = 12) in the needle and syringe (NS) group. Shown are frequencies of all cytokine-expressing (any cell expressing IFN-, TNF-, IL-2 and/or IL-17) BCG-speciﬁc CD4 (A)
and  CD8 (B) T-cell responses at 10 or 14 weeks after vaccination. Horizontal lines represent medians, boxes represent interquartile range (IQR), and whiskers the range. Each
individual vaccinee is represented by a dot. p Values were calculated using the Mann–Whitney test, comparing the wheal versus the no wheal subgroup per time point or
per  cytokine-expressing cell subset.
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Table  3
Summary of adverse events and BCG lesion by study arm.
Combined Jet injector (DSJI) Needle and syringe (NS) p-Value
Adults n = 30 n = 15 n = 15
Total  adverse events 272 126 (46.3%) 146 (53.7%) p = 0.187
Type  of AEs, n (%)
Injection site* 227 (83.5%) 108 (85.7%) 119 (81.5%) p = 0.414
Systemic 45 (16.5%) 18 (14.3%) 27 (18.5%)
Moderate and severe AEs, n (% of total AEs) 26 (9.6%) 11 (8.7%) 15 (10.2%) p = 0.098
Pain  with injection, n (% of total AEs) 5 (1.8%) 2 (1.6%) 3 (2.1%) p = 0.564
Bleeding at injection site, n (% of total AEs) 7** (2.6%) 3 (2.4%) 4 (2.7%) p = 0.454
BCG  lesion at 12 weeks
Ulcer present, n (%) 25 (83.3) 12 (80.0%) 13 (86.7%) p = 0.690
Scarring present, n (%) 29 (96.7%) 15 (100%) 14 (93.3%) p = 0.670
Infants n = 66 n = 33 n = 33
Total  adverse events, n 319 158 (49.5%) 161 (50.5%) p = 0.475
Type  of AEs, n (%)
Injection site* 279 (87.5%) 138 (87.3%) 141 (87.6%) p = 0.949
Systemic 40 (12.5%) 20 (12.7%) 20 (12.4%)
Moderate and severe AEs, n (%) 24 (7.5%) 11 (7.0%) 13 (8.1%) p = 0.325
Bleeding at injection site, n (%) 13 (4.0%)** 7 (4.4%) 6 (3.7%) p = 0.665
BCG  lesion at 12 weeks
Ulcer present, n (%) 18 (27.3%) 6 (18.2%) 12 (36.4%) p = 0.166
Scarring present, n (%) 41 (62.1%) 24 (72.7%) 17 (51.5%) p = 0.127
p-Values were calculated using Fisher’s exact test. % proportions are shown per column category (combined, DSJI, NS).
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p* AEs were classiﬁed as “injection site reactions” if they occurred at the site of vacc
fter  vaccination and throughout all study visits.
** All cases of bleeding were mild with drops of blood only.
ll those with DSJI did form wheals. In the vaccinations that formed
 wheal, however, the median wheal diameter was  similar between
dministration methods. This suggests a greater variability in suc-
essful deposition of vaccine ﬂuid intradermally with NS (observed
heal versus no observed wheal), but equal performance once the
uid is deposited in the correct layer. The difference in wheal for-
ation between DSJI and NS may  have been magniﬁed in infants, as
ompared to adults, by age-speciﬁc skin characteristics. The non-
ormation of a wheal with NS may  be associated with Mantoux
echnique failure. The research nurses in our study were expe-
ienced vaccinators with as much or more ﬁeld experience than
urses doing routine BCG vaccinations in the clinics. Even in those
ptimal research conditions, it appeared that these nurses were
rone to inconsistent Mantoux technique performance. However,
ny differences in injection performance in infants were not asso-
iated with differences in BCG reactogenicity or immunogenicity,
hich suggests that the BCG dosage deposited by NS was  not
arkedly different in infants with or without wheals.
Vaccinations with the DSJI were “wetter” immediately post-
accination, with all injections in the adults noted as being “damp”
nd more vaccinations in the infant DSJI group measuring more
han 5 L of ﬂuid on the skin surface (5 L represents 10% of the
njected volume in infants). The implication of small volumes of
njected ﬂuid remaining on the skin surface is unclear. We  sur-
ise that small-volume skin ﬂuid deposition is characteristic of
he DSJI administration technique, but not necessarily indicative
f sub-optimal intradermal deposition of BCG vaccine. This sug-
estion is supported by our ﬁndings regarding site of injection
heal diameter, reactogenicity, and immunogenicity. However,
e acknowledge that wheal diameter and estimation of skin ﬂuid
eposition are proxy measures of clinical injection performance
nd their validity in determining a successful intradermal vacci-
ation is uncertain. This issue was highlighted by poor correlation
etween post-vaccination wheal diameter and skin ﬂuid deposition
nd between immunogenicity readouts and wheal diameter.
In the infants vaccinated with NS in whom no wheal formed
nd in whom little or no ﬂuid leakage was  observed, it is
ossible that intradermal technique failure resulted in vaccine ﬂuidministration; all other AEs were classiﬁed as “systemic.” AEs were recorded 30 min
deposition into the subcutaneous or intramuscular skin layer. The
relative “wetness” of wheal-forming DSJI vaccinations may  imply
some deposition of ﬂuid across more than one layer of the skin.
Subcutaneous BCG administration may  be a risk factor for BCG com-
plications such as lymphadenopathy and abscess formation [18].
Although we did not observe these complications, it is possible that
an association between complications and injections that do not
form a wheal may  be more evident in a larger sample size. BCG
leaked onto the skin during administration may  carry a very small
risk of environmental exposure to the community, particularly to
immunodeﬁcient individuals at greater risk of disseminated BCG.
Although BCG has been in use for decades, there is a paucity of
data to inform the expected “benchmark” post-vaccination wheal
diameter; the estimation of skin ﬂuid deposition by the Mantoux
NS method; or the diameter of characteristic BCG lesion parame-
ters such as erythema, induration, ulceration, and scar formation in
infants. The median wheal diameter of 3 mm,  in infants receiving
the standard 0.05-mL dose of BCG, may  serve as a useful reference
for future studies.
Although adequate for the analysis of safety and immunogenic-
ity, our trial design was limited by a relatively wide time interval
between visits that precluded a detailed analysis of the evolution of
the BCG lesion over time. The proportion of BCG lesions that formed
characteristic scars at 14 weeks in infants (62%) was  lower than
expected [18,19]. However, at the 12-week follow-up, 10 infants
(2 DSJI, 8 NS) still had active lesions with erythema, induration, or
ulceration, which may  have developed scarring with longer follow-
up. Therefore, ideally, the length of follow-up should have been
longer.
As markers of BCG “vaccine take” in infants, we  measured BCG-
speciﬁc CD4 and CD8 T-cell responses. We chose post-vaccination
time points at 10 and 14 weeks, as previous experience had iden-
tiﬁed these as the indicators of peak response and durability of
response, respectively [6]. Frequencies and cytokine co-expression
patterns of BCG-speciﬁc T-cell responses did not differ between the
DSJI and NS groups. While these responses do not predict clinical
efﬁcacy of the vaccine, they were considered adequate for the study
objectives to distinguish a potential difference in immune response
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etween the two vaccination methods [20]. Notably, in a previ-
us study of Japanese BCG administration, in which intradermal
S administration was compared with percutaneous administra-
ion, different levels of soluble IFN- and IL-2 after BCG stimulation
ere observed [21]. However, frequencies of IFN--expressing CD4
nd CD8 T-cells, measured by whole blood ICS assay, were not dif-
erent. This may  suggest that the short-term ICS assay may  not be
deal for detecting administration route-dependent differences in
CG-induced immunity.
Our data demonstrate that BCG administration by DSJI is as safe
nd immunogenic as conventional Mantoux NS administration. It
ppears that BCG vaccination of newborn infants via DSJI is more
ikely to deliver an appropriate intradermal wheal, compared to
S, despite leaving more ﬂuid on the skin surface. The signiﬁcance
f this ﬁnding, in terms of injection performance, needs further
xploration. Follow-up research is also required to investigate the
ost-effectiveness and feasibility of such devices for national vacci-
ation programs considering multiple factors, such as reduced risk
f needlestick injuries, reduced waste-management costs, and the
otential for fewer staff resources due to a simpliﬁed vaccination
echnique. The potential application for this technology for BCG
accination is large, given the global coverage of BCG vaccination,
nd further investigation is justiﬁed.
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